Evidence guide · South Africa
Semax and KPV: the 'brain' and 'gut' peptides, and what the FDA found
Semax and KPV are two of six peptides in the October 2026 US compounding policy. What each one is, what the FDA found on human evidence and safety, and the rules in the UK, US, UAE and South Africa.
Review type: research summary. This page summarises published research and product labels, cited below.
Semax and KPV are two of the six peptides named in the US Department of Health and Human Services (HHS) compounding policy announced in the Federal Register on 30 October 2026, alongside BPC-157, epitalon, MOTS-c and TB-500. Semax is sold as a nasal spray or injection for focus, memory and mood; KPV is sold as a gut, skin and anti-inflammatory peptide. Both were reviewed by the US Food and Drug Administration (FDA) for an advisory committee meeting in July 2026.
Short answer: the two peptides have very different records, and neither is strong. Semax is a registered medicine in Russia, and the FDA found small studies in people, but the human results it could assess were weak. Of the studies it found, one reported no side effects and the others did not discuss them. For KPV, the FDA found no information on its use in people at all: no trials, no pharmacokinetic studies and no case reports. Its anti-inflammatory reputation rests on cell and mouse experiments.
What Semax is
Semax is a synthetic seven-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro) modelled on a fragment of adrenocorticotropic hormone (ACTH). The FDA briefing describes it as an analogue of the ACTH 4-10 fragment that lacks the hormone's corticotropic and melanotropic properties. The Pro-Gly-Pro ending is thought to make it more resistant to breakdown by enzymes. Semax is a registered drug in Russia, available as 0.1% and 1% nasal drops, and there is no monograph for it in the European, Japanese or International Pharmacopoeias.
The FDA's May 2026 review lists the uses Semax is marketed for online: anxiety, depression, attention and memory, stroke, nerve regeneration, diabetic neuropathy, ADHD, opioid withdrawal, ALS, Parkinson's disease, Alzheimer's disease, dys-circulatory encephalopathy, optic nerve atrophy, pain and stomach protection. Products include injectables, nasal sprays and a 50:50 mix with another peptide, Selank. One website offers a 30 mg product "for research purposes only" and lists a nasal spray and injection as ways to use it. None of the websites the FDA reviewed said whether their product contained the free base, a salt form or an ester.
What KPV is
KPV is a three-amino-acid peptide, lysine-proline-valine, a fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), a neuropeptide made in the pituitary gland. It was nominated to the FDA as a 0.1% cream or gel for wound healing and inflammatory conditions such as psoriasis and eczema. The FDA judged it not well characterised: names are used inconsistently, and the certificate of analysis supplied with the nomination named one form in its title and gave the chemical formula of another.
Online, according to the FDA, KPV is promoted for inflammatory conditions, wound healing, skin health, gut health, immune support, inflammatory bowel disease, Crohn's disease, mast cell activation syndrome, histamine intolerance, Lyme disease, mould toxicity and pain, among others. It is offered as injectable, oral, topical and nasal spray products, and in multi-peptide "regenerative combo" products with BPC-157, TB-500 and other substances.
What the evidence says
Grades used here: Strong (consistent results from several good-quality human trials), Moderate (good trials, but few or with mixed results), Limited (small or low-quality human studies), Insufficient (too little human research to judge) and Evidence of harm. Animal and cell studies do not count towards a grade.
Semax for brain function, stroke and pain: Insufficient
Semax was nominated for analgesia, ADHD and use as a nootropic. The FDA evaluated it for cerebral ischaemia (too little blood flow to the brain, as in stroke), migraine and trigeminal neuralgia. It did not evaluate ADHD because it found no supporting literature, and treated the nootropic claim as part of the cerebral ischaemia review. Russian-language studies on cerebral ischaemia were not assessed because no English translation of the full papers was available.
- Cerebral ischaemia: the only usable source was a 2002 meeting abstract. It did not say how many patients took part and gave no clinical outcomes before and after treatment.
- Migraine: in a 1996 study, 12 adults each received one intranasal dose. Four of the 12 reported that their headache stopped 90 to 120 minutes later; in the other eight, pain eased but was not eliminated. There was no control group and no blinding.
- Trigeminal neuralgia: in the same study, 16 people with typical trigeminal neuralgia showed no change in pain. Of 9 with a dental subtype, 6 reported pain resolving and 3 reported less severe pain, but the frequency and duration of attacks did not fall. The authors concluded that Semax does not show analgesic activity by itself because trigeminal somatosensory evoked potentials did not change.
The FDA's conclusion: there is insufficient evidence to support Semax for cerebral ischaemia, migraine or trigeminal neuralgia, and professional guidelines for these conditions do not discuss it. Memory and focus were not evaluated as separate uses: the FDA folded the nootropic claim into its cerebral ischaemia review, where the only usable source was the meeting abstract. Anxiety and depression, also marketed online, were not evaluated.
KPV for gut, skin and inflammation: Insufficient
None of the nine references in the KPV nomination gave KPV to living people. They include animal studies of alpha-MSH and related peptides, experiments on human cells, and one skin-permeation experiment on cadaver skin. The FDA found no published study in which a product containing KPV was used in humans, and US outsourcing facilities reported no KPV products from January 2017 to June 2025.
The laboratory work is more interesting. In a 2008 study from Emory University, nanomolar concentrations of KPV damped inflammatory signalling in human intestinal and immune cells, and KPV given in drinking water reduced chemically induced colitis in mice. A 2010 study from the same group delivered KPV to the colon of mice in nanoparticles. These are mouse and cell results; the FDA notes that the molecular targets behind KPV's effects remain unknown. For skin use, an experiment on cadaver skin found KPV does not pass through skin well, which the FDA says could limit both its usefulness as a cream and its absorption into the body.
Safety: what is known
For Semax, the FDA found no pharmacokinetic studies in people by any route and no safety data at all for injection under the skin. The human records it could find covered intranasal use only: roughly 33 to 47 healthy adults, 69 adults with medical conditions and 451 children with depression or with tics, including Tourette syndrome. Most of those reports did not discuss side effects, and one reported none. A search of the FDA's adverse event database to 3 December 2025 found one report: a consumer reported eye pain and burning in May 2024 after using Semax 0.1% nasal drops bought online, reported being hospitalised, and said the eye pain had not resolved when she filed the report in May 2025.
The FDA flagged two specific concerns. One source described possible anti-clotting effects, which raises a question about bleeding risk, particularly for people who bleed easily or take other medicines that increase bleeding risk. In mice, Semax also boosted amphetamine-induced dopamine release in the striatum, a brain region; the FDA notes that increased dopamine tone there is a response typically induced by drugs of abuse such as cocaine, and it found no studies of whether Semax has addictive properties. The FDA found no standard animal studies of acute or repeat-dose toxicity or reproductive toxicity, and no adequate cancer study.
For KPV, the FDA found nothing on human safety: no clinical studies or human exposure data by any route, no reports in its adverse event databases (searched to 3 December 2025) and no case reports. It also found no pharmacokinetic studies and none of the standard animal toxicity studies. Its conclusion is that the potential safety risks in humans are unknown.
For both peptides the FDA raised the same further concern: they could provoke immune reactions, and peptides can clump together (aggregate), which can raise that risk and change how a product works. The FDA notes that peptides as short as two amino acids have been shown to aggregate.
What is in the vial
Quality is a separate risk. Researchers at Sciensano in Brussels identified Selank and Semax in two suspicious seized preparations encountered at the end of 2017 and 2018, and an online search by the same team found such peptides freely available as powder for injection or in nasal sprays. A 2026 review of peptides in sport and bodybuilding, which names KPV among peptides promoted for recovery and anti-inflammatory effects, says the largely unregulated supply chain means products are often mislabelled or contaminated.
What the FDA recommended
The nominations for both were withdrawn, and the FDA evaluated both peptides on its own initiative. Its briefings, dated 11 May 2026 for Semax and 12 May 2026 for KPV, concluded that the evaluation criteria weigh against adding either one to the list of substances US pharmacies may use in compounding. KPV was on the advisory committee agenda for 23 July 2026 and Semax for 24 July 2026. The FDA's category 2 page lists both among bulk drug substances nominated but withdrawn, noting the potential for immune reactions with Semax and that it has not identified any human exposure data for KPV.
Our view
- Semax has some human history, mostly in Russia, but the studies the FDA could use for stroke, migraine and nerve pain were small. The migraine and nerve-pain study had no control group. Most of the human reports did not discuss side effects. The marketing claims for memory, focus and mood go well beyond that record.
- KPV has an interesting laboratory story in gut inflammation and no published human data. No published study the FDA found has examined the gut, skin or histamine claims made for it online in people.
- Do not inject either peptide bought online. The FDA found no safety data for injected Semax, and no study in which KPV was given to a living person.
- If you bleed easily or take medicines that increase bleeding risk, the possible anti-clotting effect of Semax is a reason to speak to your doctor first.
- For inflammatory bowel disease, eczema, psoriasis, migraine or stroke recovery, ask your doctor about treatments with human evidence and about clinical trials, rather than self-sourcing peptides.
South African rules
The US policy has no legal effect in South Africa. SAHPRA names Semax and Selank among its examples of illegally marketed peptide products, sold through online platforms, social media, gyms, wellness centres and informal suppliers. Under the Medicines and Related Substances Act 101 of 1965, any product intended to treat, prevent or alter bodily functions must be registered with SAHPRA before it can be sold. SAHPRA warns against self-administration without medical supervision, especially for products bought online. Report side effects to adr@sahpra.org.za.
FAQ
Is Semax approved anywhere?
It is a registered drug in Russia, as nasal drops. It is not a component of any FDA-approved drug in the US, and there is no monograph for it in the European, Japanese or International Pharmacopoeias.
Is KPV a supplement?
No. The FDA reviewed it as a bulk drug substance proposed for compounding, and the US policy treats it as a drug ingredient. It is not part of any FDA-approved drug.
Does Semax improve memory or focus?
There is no good evidence. The FDA treated the nootropic claim as part of its cerebral ischaemia review and found insufficient evidence of effectiveness. The only human source it could use was a meeting abstract that did not report how many patients took part or any clinical result.
Does KPV help gut inflammation?
It reduced colitis in mice in laboratory studies. No published study has given KPV to people with gut inflammation, so there is no human evidence that it helps.
Sources
These are the documents this page relies on.
- FDA Briefing Document: FDA evaluation of Semax-related bulk drug substances (Semax (free base) and Semax acetate), Pharmacy Compounding Advisory Committee meeting, 23 and 24 July 2026US Food and Drug Administration
- FDA Briefing Document: FDA evaluation of KPV-related bulk drug substances (KPV (free base) and KPV acetate), Pharmacy Compounding Advisory Committee meeting, 23 and 24 July 2026US Food and Drug Administration
- Pharmacy Compounding Advisory Committee meeting, 23 and 24 July 2026: final agendaUS Food and Drug Administration
- Certain bulk drug substances for use in compounding that may present significant safety risks (category 2 and bulk drug substances nominated but withdrawn; content current as of 22 April 2026)US Food and Drug Administration
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178Gastroenterology (PubMed 18061177)
- Laroui H, Dalmasso G, Nguyen HT, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010;138(3):843-853.e1-2Gastroenterology (PubMed 19909746)
- Vanhee C, Francotte A, Janvier S, Deconinck E. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations. Drug Test Anal. 2020;12(3):371-381Drug Testing and Analysis (PubMed 31667971)
- Coutinho LFD, de Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. J Sports Med Phys Fitness. 2026;66(7):880-885Journal of Sports Medicine and Physical Fitness (PubMed 41880199)
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B (October 2026)US Department of Health and Human Services
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Notice of availability, Docket HHS-OASH-2026-0496. Federal Register 91(209):68526-68527, 30 October 2026Federal Register (GovInfo)
- NABP memo to state boards of pharmacy: HHS Peptide Enforcement Discretion Policy and October 30 FDA Engagement, 28 October 2026National Association of Boards of Pharmacy (via Idaho Division of Occupational and Professional Licenses)
- Peptide products: public informationSAHPRA